Digital therapeutics and their impact on society

Elisa del Galdo|14th January 2020

In the 20th century, research, technology and new novel treatments have enabled us to increase the average lifespan by 25 years, but our healthspan has not increased accordingly. We live longer, but not necessarily better – unfortunately, our quality of life has not improved throughout these added years. This is in part due to the explosive, bordering on unmanageable, increase in chronic diseases, such as cardiovascular disease, diabetes, Alzheimer’s disease, obesity and asthma.

Often these conditions are not experienced in isolation, resulting in many patients managing two or more comorbidities, leading to complex health problems that are more difficult to monitor and manage.

The World Health Organisation reports that by 2020 chronic diseases will account for three-quarters of all deaths worldwide and will reduce the quality of life for patients and their caregivers. With the average cost of managing comorbid chronic patients in the UK estimated to be eight times that of a relatively healthy patient, the economic impact of these illnesses on healthcare systems is immense.

To solve this problem, our systems must be more efficient and more effective in the management and prevention of chronic diseases.

Digital therapeutics, such as smartphone apps and wearable technology, can be used to relieve some of the pressure. They can be used in a multitude of ways to support the effective delivery of healthcare.

This includes monitoring, motivating, changing behaviour, facilitating communication, and helping to manage processes, all while collecting valuable data. When done well, these tools can facilitate more meaningful interactions between patients and healthcare professionals.

Our content has moved

Blue Latitude Health|18th November 2020

We’re posting all new articles on our parent website fishawack.com

read more

Fishawack Health launches Delta Magazine

Blue Latitude Health|17th November 2020

Our parent company Fishawack Health has launched a new magazine with a first issue unpacking rare disease.

read more

In the precision medicine era, the line between products and services is blurred

Amit Sheinholtz and Ilektra Safari|27th August 2020

Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?

read more